KLM Royal Dutch Airlines (KLMR)

Verve Therapeutics Cash Flow Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	69	713	743	-1,259	-1,547
Depreciation & Amortization	973	915	905	860	968
Other Amortization	83	64	80	82	81
Asset Writedown & Restructuring Costs	-	-	8	-	-
Loss (Gain) From Sale of Investments	-	-	-	-	-16
Loss (Gain) on Equity Investments	-9	-5	-	-3	-3
Other Operating Activities	191	-186	-292	786	4
Change in Accounts Receivable	123	-158	-82	-79	333
Change in Inventory	-13	-76	-46	-48	103
Change in Accounts Payable	-82	-21	300	198	-306
Change in Unearned Revenue	-4	17	421	-	-
Change in Other Net Operating Assets	-369	12	377	663	89
Operating Cash Flow	962	1,275	2,414	1,200	-294
Operating Cash Flow Growth	-24.55%	-47.18%	101.17%	-	-
Capital Expenditures	-1,243	-989	-565	-381	-655
Sale of Property, Plant & Equipment	79	579	65	32	85
Sale (Purchase) of Intangibles	-109	-97	-80	-132	-111
Investment in Securities	48	-44	74	-8	11
Other Investing Activities	66	61	-	1	-
Investing Cash Flow	-1,159	-490	-506	-488	-670
Long-Term Debt Issued	496	401	649	577	2,092
Long-Term Debt Repaid	-644	-726	-1,605	-994	-1,365
Net Debt Issued (Repaid)	-148	-325	-956	-417	727
Common Dividends Paid	-1	-	-	-1	-19
Other Financing Activities	-212	-380	-249	34	48
Financing Cash Flow	-361	-705	-1,205	-384	756
Foreign Exchange Rate Adjustments	12	-10	11	9	-6
Net Cash Flow	-546	70	714	337	-214
Free Cash Flow	-281	286	1,849	819	-949
Free Cash Flow Growth	-	-84.53%	125.76%	-	-
Free Cash Flow Margin	-2.22%	2.37%	17.31%	13.50%	-18.54%
Free Cash Flow Per Share	-5.99	6.11	39.50	17.50	-20.27
Cash Interest Paid	217	214	177	188	136
Levered Free Cash Flow	-129.13	385	1,875	-613.38	-968.63
Unlevered Free Cash Flow	-3.5	514.38	1,986	-476.5	-866.13
Change in Net Working Capital	-45	-241	-1,220	178	437

Source: S&P Global Market Intelligence. Standard template. Financial Sources.